Browse 1,565 thyroid cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.
Most thyroid cancers grow slowly and have some of the best outcomes of any cancer, which is why some small ones can now be safely monitored instead of removed right away. A small share behave very differently: cancers that stop responding to radioactive iodine, inherited medullary thyroid cancer, and the rare but aggressive anaplastic type. Targeted medicines matched to specific gene changes have opened new options for these groups.
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
for
Solid Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT06066424
Phase 1, Recruiting
Active & Responsive
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
for
Solid Tumor, Adult, Colorectal Cancer, NSCLC,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.
Sex: All
Age: 18+
Code: NCT06051695
Phase 1, Phase 2, Recruiting
Active & Responsive
Multisite Implementation of COMPRENDO
for
Pediatric Cancer
Location: Boston MA, Birmingham AL, San Diego CA,
Sponsor: University of California, San Diego
Sex: All
Age: 18+
Code: NCT06055296
Recruiting
Active & Responsive
Biomarkers to Detect Endocrine Therapy Resistance
for
Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
Location: Madison WI
Sponsor: University of Wisconsin, Madison
Sex: All
Age: 18+
Code: NCT06067503
Phase 2, Recruiting
Active & Responsive
CARE Study: Cancer, Asian Americans, and Relationship Enrichment
for
Neoplasm
Location: Philadelphia PA
Sponsor: Fox Chase Cancer Center
Sex: All
Age: 21 - 70+
Code: NCT06782581
Recruiting
Active & Responsive
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
for
Solid Tumor, KRAS Mutation-Related Tumors
Location: Washington D.C. DC
Sponsor: Georgetown University
Sex: All
Age: 18+
Code: NCT05661201
Phase 1, Recruiting
Active & Responsive
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
for
Localized Renal Pelvis and Ureter Urothelial Carcinoma,
Location: Seattle WA
Sponsor: University of Washington
Sex: Male
Age: 18+
Code: NCT01050504
Recruiting
Active & Responsive
MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other
for
Cancer, Adjustment Disorders
Location: Rockville MD
Sponsor: Sunstone Medical
Sex: All
Age: 18+
Code: NCT05584826
Phase 2, Recruiting
Active & Responsive
PATH Program for for Severely Frail or Cognitively Impaired Patients Scheduled for Cancer Surgery.
for
Frailty, Oncology Problem, Cognitive Impairment
Location: Halifax
Sponsor: Nova Scotia Health Authority
Sex: All
Age: 70+
Code: NCT06022666
Recruiting
Active & Responsive
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
for
Advanced Solid Tumor
Location: Pittsburgh PA, Houston TX, Beverly Hills CA